MA38085A1 - Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer - Google Patents

Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Info

Publication number
MA38085A1
MA38085A1 MA38085A MA38085A MA38085A1 MA 38085 A1 MA38085 A1 MA 38085A1 MA 38085 A MA38085 A MA 38085A MA 38085 A MA38085 A MA 38085A MA 38085 A1 MA38085 A1 MA 38085A1
Authority
MA
Morocco
Prior art keywords
production
cancer
compounds
treatment
new process
Prior art date
Application number
MA38085A
Other languages
English (en)
Other versions
MA38085B1 (fr
Inventor
C Gregory Sowell
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA38085A1 publication Critical patent/MA38085A1/fr
Publication of MA38085B1 publication Critical patent/MA38085B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un procédé pour la production d'un composé de formule i. Ledit composé de formule i est un inhibiteur de mek et peut ainsi être utilisé pour traiter le cancer.
MA38085A 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer MA38085B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (fr) 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA38085A1 true MA38085A1 (fr) 2018-08-31
MA38085B1 MA38085B1 (fr) 2018-11-30

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38085A MA38085B1 (fr) 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Country Status (31)

Country Link
US (4) US9771347B2 (fr)
EP (1) EP2909188B1 (fr)
JP (2) JP6300042B2 (fr)
KR (1) KR102204520B1 (fr)
CN (2) CN108948043B (fr)
AU (1) AU2013328929B2 (fr)
BR (1) BR112015008113B1 (fr)
CA (1) CA2889466C (fr)
CL (1) CL2015000926A1 (fr)
CR (2) CR20200237A (fr)
EA (1) EA030613B1 (fr)
ES (1) ES2671502T3 (fr)
GE (1) GEP201706690B (fr)
HK (2) HK1213567A1 (fr)
HR (1) HRP20180670T1 (fr)
IL (1) IL238116B (fr)
IN (1) IN2015DN03928A (fr)
MA (1) MA38085B1 (fr)
MX (2) MX2015004660A (fr)
MY (1) MY186549A (fr)
NZ (1) NZ706723A (fr)
PE (3) PE20151494A1 (fr)
PH (1) PH12015500785A1 (fr)
PL (1) PL2909188T3 (fr)
SA (1) SA515360271B1 (fr)
SG (1) SG11201502795VA (fr)
SI (1) SI2909188T1 (fr)
TR (1) TR201807861T4 (fr)
UA (1) UA115455C2 (fr)
WO (1) WO2014059422A1 (fr)
ZA (1) ZA201502349B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
HRP20240045T1 (hr) 2015-06-30 2024-03-29 Genentech, Inc. Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
EP3496752B1 (fr) 2016-08-12 2022-05-18 Genentech, Inc. Polythérapie avec un inhibiteur de mek, un inhibiteur de l'axe pd-1 et un inhibiteur de vegf
JP2019534251A (ja) 2016-09-29 2019-11-28 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法
WO2020187674A1 (fr) 2019-03-15 2020-09-24 Sandoz Ag Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
KR20230156731A (ko) 2021-03-09 2023-11-14 제넨테크, 인크. 뇌암 치료에 이용하기 위한 벨바라페닙
JP2024514112A (ja) 2021-04-06 2024-03-28 ジェネンテック， インコーポレイテッド ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CA2186947A1 (fr) 1994-04-01 1995-10-12 Kazuo Ueda Derive d'oxime et bactericide le contenant en tant qu'ingredient actif
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (fr) 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
WO1999001426A1 (fr) 1997-07-01 1999-01-14 Warner-Lambert Company Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek
DE69836378T2 (de) * 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
EP1140046A1 (fr) 1998-12-15 2001-10-10 Warner-Lambert Company Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek
EP1143957A3 (fr) 1998-12-16 2002-02-27 Warner-Lambert Company Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
ATE310567T1 (de) 1998-12-22 2005-12-15 Warner Lambert Co Chemotheriapie mit einem antimitotischen mittel und einem mek inhibitor
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
CA2358438A1 (fr) 1999-01-07 2000-07-13 David Thomas Dudley Methode antivirale utilisant des inhibiteurs de mek
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
WO2000042003A1 (fr) 1999-01-13 2000-07-20 Warner-Lambert Company Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek
CN1149204C (zh) 1999-01-13 2004-05-12 沃尼尔·朗伯公司 1-杂环取代的二芳基胺
CA2348236A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
ID30439A (id) 1999-01-13 2001-12-06 Warner Lambert Co Benzoheterosiklus dan penggunaannya sebagai penghambat mek
CA2349180A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4'heteroaryle diarylamines
CA2378381A1 (fr) 1999-07-16 2001-01-25 Warner-Lambert Company Traitement de douleurs chroniques au moyen d'inhibiteurs de mek
EP1202732A2 (fr) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Methode de traitement de la douleur chronique utilisant des inhibiteurs mek
NZ515567A (en) 1999-07-16 2004-03-26 Warner Lambert Co Method for treating chronic pain using MEK inhibitors
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
NZ517829A (en) 1999-09-17 2004-12-24 Millennium Pharm Inc Benzamides and related inhibitors of factor Xa
CA2403017A1 (fr) 2000-03-15 2001-09-20 Warner-Lambert Company Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
CZ2003477A3 (cs) * 2000-08-25 2003-10-15 Warner - Lambert Company Llc Způsob přípravy N-aryl-anthranilových kyselin a jejich derivátů
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
BR0213696A (pt) 2001-10-31 2004-10-26 Pfizer Prod Inc Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
PT2275102E (pt) 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TW200406203A (en) 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
WO2003103590A2 (fr) 2002-06-11 2003-12-18 Merck & Co., Inc. Inhibiteurs de la kinase p38 (halo-benzo carbonyl)heterobicyclique
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (fr) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Association d'un inhibiteur de cible mammalienne de rapamycine (mtor) et d'un inhibiteur de la tyrosine kinase aux fins du de traitement de neoplasmes
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1641804A1 (fr) 2003-06-20 2006-04-05 Celltech R & D Limited Derives de thienopyridone en tant qu inhibiteurs de kinase
WO2005000818A1 (fr) 2003-06-27 2005-01-06 Warner-Lambert Company Llc Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (fr) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazoles n-methyle-substitues
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005051301A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
ATE384058T1 (de) 2003-12-08 2008-02-15 Hoffmann La Roche Thiazolderivate
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
KR101318012B1 (ko) * 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
WO2006061712A2 (fr) 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EA019983B1 (ru) * 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008076415A1 (fr) 2006-12-14 2008-06-26 Exelixis, Inc. Procédés d'utilisation d'inhibiteurs de mek
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
ES2702891T3 (es) 2014-02-07 2019-03-06 Sumitomo Chemical Co Método para producir (R)-1,1,3-Trimetil-4-aminoindano
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
PE20191818A1 (es) 2019-12-27
PL2909188T3 (pl) 2018-08-31
SG11201502795VA (en) 2015-05-28
CR20200237A (es) 2020-07-26
MX2015004660A (es) 2015-08-07
PH12015500785B1 (en) 2015-06-15
PE20200387A1 (es) 2020-02-24
US20170349569A1 (en) 2017-12-07
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
HK1213567A1 (zh) 2016-07-08
WO2014059422A1 (fr) 2014-04-17
US10239858B2 (en) 2019-03-26
US20150210668A1 (en) 2015-07-30
PE20151494A1 (es) 2015-11-06
CA2889466A1 (fr) 2014-04-17
EP2909188B1 (fr) 2018-03-07
HRP20180670T1 (hr) 2018-07-13
CN108948043A (zh) 2018-12-07
US11414396B2 (en) 2022-08-16
SA515360271B1 (ar) 2016-05-19
HK1213878A1 (zh) 2016-07-15
MX2020005533A (es) 2020-10-12
IN2015DN03928A (fr) 2015-10-02
JP6300042B2 (ja) 2018-03-28
US20200392104A1 (en) 2020-12-17
ES2671502T3 (es) 2018-06-06
BR112015008113A2 (pt) 2017-07-04
JP2018052973A (ja) 2018-04-05
US10793541B2 (en) 2020-10-06
SI2909188T1 (en) 2018-07-31
UA115455C2 (uk) 2017-11-10
CN104837826B (zh) 2018-07-27
KR102204520B1 (ko) 2021-01-20
CN104837826A (zh) 2015-08-12
KR20150067339A (ko) 2015-06-17
ZA201502349B (en) 2019-12-18
CR20150245A (es) 2015-11-19
AU2013328929B2 (en) 2018-01-04
CA2889466C (fr) 2021-09-14
CL2015000926A1 (es) 2015-08-28
EA030613B1 (ru) 2018-08-31
GEP201706690B (en) 2017-06-26
BR112015008113B1 (pt) 2022-05-24
EP2909188A1 (fr) 2015-08-26
AU2013328929A1 (en) 2015-04-30
NZ706723A (en) 2018-07-27
TR201807861T4 (tr) 2018-06-21
IL238116B (en) 2018-06-28
EA201590700A1 (ru) 2015-09-30
JP2015533175A (ja) 2015-11-19
MY186549A (en) 2021-07-26
US9771347B2 (en) 2017-09-26
PH12015500785A1 (en) 2015-06-15
CN108948043B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
MA38085B1 (fr) Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
CY1122272T1 (el) ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
EA201891553A1 (ru) Ингибиторы syk
MA44820B1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
PH12017501419B1 (en) Therapeutically active compounds and their methods of use
EA201690094A1 (ru) Ингибиторы syk
MA40076A (fr) Inhibiteurs de syk
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
UA110338C2 (en) Chemical compounds
EA201691727A1 (ru) Фосфонатные соединения для лечения опосредованных комплементом нарушений
PH12016500225A1 (en) Novel quinoline-substituted compound
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
EA201391591A1 (ru) Лечение множественной миеломы
MA39048A1 (fr) Nouveaux inhibiteurs de la dgat2
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA37676A1 (fr) Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
MA35534B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
MA37685B1 (fr) Composés acide diméthyl-benzoïque inhibiteurs selectifs de l'ep4 pour utilisation dans le traitement d'etats pathologiques inflammatoires tels que l'arthrite
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego
MA35887B1 (fr) Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2